Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study ID
NCT03115255
Status
Completed

Conditions

  • Infant, Premature, Diseases

Eligibility Criteria

Sex
ALL
Age
4 Weeks - 3 Months
Healthy Volunteers
Not accepted

Interventions

  • intravitreal ranibizumab — DRUG
    0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)

Study Details

To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab

Key Dates

First listed
Apr 14, 2017
Start date
May 1, 2017
Status verified
Apr 2018
Primary completion
May 31, 2018
Completion
Jun 30, 2018

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: serum VEGF level
    Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab

Primary Outcome Measure

The effect of intravitreal ranibizumab on serum VEGF level [ Time Frame: 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab ]

Related Studies